RecruitingNCT06130046

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

Sponsor

University of Rome Tor Vergata

Enrollment

300 participants

Start Date

Dec 1, 2022

Study Type

OBSERVATIONAL

Conditions

Liver Transplant; Complications Kidney Transplant; Complications

Summary

To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria2

Kidney transplant recipient at our Institution
Liver transplant recipient at our Institution

Exclusion Criteria4

Re-transplantation
Dual kidney transplantation
Combined transplant (kidney-liver, kidney-pancreas)
Autoimmune disease as indication to transplant

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMR-proADM dosage

Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U

Locations(1)

University of Rome Tor Vergata

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06130046

Related Trials

Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program

NCT066888251 location

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

NCT067989095 locations